MAGEA4 and synovial sarcoma: IMC-C103C targets MAGE-A4 and is being tested in a phase I clinical trial (NCT03973333) against the following several solid tumors: synovial sarcoma, non–small-cell lung, gastric, head and neck, and ovarian cancer.